Naftidrofuryl in Chronic Arterial Disease. Results of a Controlled Multicenter Study

In a double blind, randomized multicenter study naftidrofuryl, a vasoactive substance, was compared with placebo in the treatment of 104 patients with chronic arterial occlusive disease. After a run-in period of four weeks the pa tients received either naftidrofuryl (600mg daily) or placebo over 12...

Full description

Saved in:
Bibliographic Details
Published in:Angiology 1984-11, Vol.35 (11), p.701-708
Main Authors: Trübestein, G., Böhme, H., Heidrich, H., Heinrich, F., Hirche, H., Maass, U., Mörl, H., Rudofsky, G.
Format: Article
Language:English
Subjects:
Adult
Arterial Occlusive Diseases - drug therapy
Blood Flow Velocity
Blood Pressure
Chronic Disease
Clinical Trials as Topic
Double-Blind Method
Female
Furans - therapeutic use
Humans
Male
Middle Aged
Nafronyl - therapeutic use
Placebos
Statistics as Topic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c369t-f133da0b9e22ee8325765ff57e6ede439f2d0cfa9fd14b5c8e076d32ccb27c4b3
cites cdi_FETCH-LOGICAL-c369t-f133da0b9e22ee8325765ff57e6ede439f2d0cfa9fd14b5c8e076d32ccb27c4b3
container_end_page 708
container_issue 11
container_start_page 701
container_title Angiology
container_volume 35
creator Trübestein, G.
Böhme, H.
Heidrich, H.
Heinrich, F.
Hirche, H.
Maass, U.
Mörl, H.
Rudofsky, G.
description In a double blind, randomized multicenter study naftidrofuryl, a vasoactive substance, was compared with placebo in the treatment of 104 patients with chronic arterial occlusive disease. After a run-in period of four weeks the pa tients received either naftidrofuryl (600mg daily) or placebo over 12 weeks. The pain-free and the total walking distances improved significantly in both groups. However, the difference in the improvement of the pain-free walking distance was significant (p < 0.02) in favour of naftidrofuryl. There also was a difference in the improvement of the total walking distance in favour of naftidrofuryl which was not significant. The results indicate that naftidrofuryl has a beneficial effect on the symp toms and lengthens the painfree walking distance in patients with arterial occlu sive disease.
doi_str_mv 10.1177/000331978403501103
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_81335621</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_000331978403501103</sage_id><sourcerecordid>20071702</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-f133da0b9e22ee8325765ff57e6ede439f2d0cfa9fd14b5c8e076d32ccb27c4b3</originalsourceid><addsrcrecordid>eNqFkEtPwzAQhC0EKqXwB5CQfOKW1o84To5VeEoFJCjnyLHXkCqNi50c-u9x1YoLEpxWu_PNrDQIXVIypVTKGSGEc1rIPCVcEEoJP0JjWqQkoUKmx2i8A5IdcYrOQljFVVCSjdAo43meMjFGy2dl-8Z4Zwe_bXHT4fLTu67ReO578I1q8U0TQAWY4lcIQ9sH7CxWuHRd713bgsFP8dpo6CKP3_rBbM_RiVVtgIvDnKD3u9tl-ZAsXu4fy_ki0Twr-sRSzo0idQGMAeScCZkJa4WEDAykvLDMEG1VYQ1Na6FzIDIznGldM6nTmk_Q9T53493XAKGv1k3Q0LaqAzeEKo8PRMbovyAjRFJJWATZHtTeheDBVhvfrJXfVpRUu86r351H09UhfajXYH4sh5KjPtvrQX1AtXKD72IrfyV-A3KEiaU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20071702</pqid></control><display><type>article</type><title>Naftidrofuryl in Chronic Arterial Disease. Results of a Controlled Multicenter Study</title><source>SAGE Complete Deep Backfile Purchase 2012</source><creator>Trübestein, G. ; Böhme, H. ; Heidrich, H. ; Heinrich, F. ; Hirche, H. ; Maass, U. ; Mörl, H. ; Rudofsky, G.</creator><creatorcontrib>Trübestein, G. ; Böhme, H. ; Heidrich, H. ; Heinrich, F. ; Hirche, H. ; Maass, U. ; Mörl, H. ; Rudofsky, G.</creatorcontrib><description>In a double blind, randomized multicenter study naftidrofuryl, a vasoactive substance, was compared with placebo in the treatment of 104 patients with chronic arterial occlusive disease. After a run-in period of four weeks the pa tients received either naftidrofuryl (600mg daily) or placebo over 12 weeks. The pain-free and the total walking distances improved significantly in both groups. However, the difference in the improvement of the pain-free walking distance was significant (p &lt; 0.02) in favour of naftidrofuryl. There also was a difference in the improvement of the total walking distance in favour of naftidrofuryl which was not significant. The results indicate that naftidrofuryl has a beneficial effect on the symp toms and lengthens the painfree walking distance in patients with arterial occlu sive disease.</description><identifier>ISSN: 0003-3197</identifier><identifier>EISSN: 1940-1574</identifier><identifier>DOI: 10.1177/000331978403501103</identifier><identifier>PMID: 6388425</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><subject>Adult ; Arterial Occlusive Diseases - drug therapy ; Blood Flow Velocity ; Blood Pressure ; Chronic Disease ; Clinical Trials as Topic ; Double-Blind Method ; Female ; Furans - therapeutic use ; Humans ; Male ; Middle Aged ; Nafronyl - therapeutic use ; Placebos ; Statistics as Topic</subject><ispartof>Angiology, 1984-11, Vol.35 (11), p.701-708</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-f133da0b9e22ee8325765ff57e6ede439f2d0cfa9fd14b5c8e076d32ccb27c4b3</citedby><cites>FETCH-LOGICAL-c369t-f133da0b9e22ee8325765ff57e6ede439f2d0cfa9fd14b5c8e076d32ccb27c4b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/000331978403501103$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/000331978403501103$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21845,27924,27925,45082,45470</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6388425$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Trübestein, G.</creatorcontrib><creatorcontrib>Böhme, H.</creatorcontrib><creatorcontrib>Heidrich, H.</creatorcontrib><creatorcontrib>Heinrich, F.</creatorcontrib><creatorcontrib>Hirche, H.</creatorcontrib><creatorcontrib>Maass, U.</creatorcontrib><creatorcontrib>Mörl, H.</creatorcontrib><creatorcontrib>Rudofsky, G.</creatorcontrib><title>Naftidrofuryl in Chronic Arterial Disease. Results of a Controlled Multicenter Study</title><title>Angiology</title><addtitle>Angiology</addtitle><description>In a double blind, randomized multicenter study naftidrofuryl, a vasoactive substance, was compared with placebo in the treatment of 104 patients with chronic arterial occlusive disease. After a run-in period of four weeks the pa tients received either naftidrofuryl (600mg daily) or placebo over 12 weeks. The pain-free and the total walking distances improved significantly in both groups. However, the difference in the improvement of the pain-free walking distance was significant (p &lt; 0.02) in favour of naftidrofuryl. There also was a difference in the improvement of the total walking distance in favour of naftidrofuryl which was not significant. The results indicate that naftidrofuryl has a beneficial effect on the symp toms and lengthens the painfree walking distance in patients with arterial occlu sive disease.</description><subject>Adult</subject><subject>Arterial Occlusive Diseases - drug therapy</subject><subject>Blood Flow Velocity</subject><subject>Blood Pressure</subject><subject>Chronic Disease</subject><subject>Clinical Trials as Topic</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Furans - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nafronyl - therapeutic use</subject><subject>Placebos</subject><subject>Statistics as Topic</subject><issn>0003-3197</issn><issn>1940-1574</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><recordid>eNqFkEtPwzAQhC0EKqXwB5CQfOKW1o84To5VeEoFJCjnyLHXkCqNi50c-u9x1YoLEpxWu_PNrDQIXVIypVTKGSGEc1rIPCVcEEoJP0JjWqQkoUKmx2i8A5IdcYrOQljFVVCSjdAo43meMjFGy2dl-8Z4Zwe_bXHT4fLTu67ReO578I1q8U0TQAWY4lcIQ9sH7CxWuHRd713bgsFP8dpo6CKP3_rBbM_RiVVtgIvDnKD3u9tl-ZAsXu4fy_ki0Twr-sRSzo0idQGMAeScCZkJa4WEDAykvLDMEG1VYQ1Na6FzIDIznGldM6nTmk_Q9T53493XAKGv1k3Q0LaqAzeEKo8PRMbovyAjRFJJWATZHtTeheDBVhvfrJXfVpRUu86r351H09UhfajXYH4sh5KjPtvrQX1AtXKD72IrfyV-A3KEiaU</recordid><startdate>198411</startdate><enddate>198411</enddate><creator>Trübestein, G.</creator><creator>Böhme, H.</creator><creator>Heidrich, H.</creator><creator>Heinrich, F.</creator><creator>Hirche, H.</creator><creator>Maass, U.</creator><creator>Mörl, H.</creator><creator>Rudofsky, G.</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>198411</creationdate><title>Naftidrofuryl in Chronic Arterial Disease. Results of a Controlled Multicenter Study</title><author>Trübestein, G. ; Böhme, H. ; Heidrich, H. ; Heinrich, F. ; Hirche, H. ; Maass, U. ; Mörl, H. ; Rudofsky, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-f133da0b9e22ee8325765ff57e6ede439f2d0cfa9fd14b5c8e076d32ccb27c4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>Adult</topic><topic>Arterial Occlusive Diseases - drug therapy</topic><topic>Blood Flow Velocity</topic><topic>Blood Pressure</topic><topic>Chronic Disease</topic><topic>Clinical Trials as Topic</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Furans - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nafronyl - therapeutic use</topic><topic>Placebos</topic><topic>Statistics as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Trübestein, G.</creatorcontrib><creatorcontrib>Böhme, H.</creatorcontrib><creatorcontrib>Heidrich, H.</creatorcontrib><creatorcontrib>Heinrich, F.</creatorcontrib><creatorcontrib>Hirche, H.</creatorcontrib><creatorcontrib>Maass, U.</creatorcontrib><creatorcontrib>Mörl, H.</creatorcontrib><creatorcontrib>Rudofsky, G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Angiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Trübestein, G.</au><au>Böhme, H.</au><au>Heidrich, H.</au><au>Heinrich, F.</au><au>Hirche, H.</au><au>Maass, U.</au><au>Mörl, H.</au><au>Rudofsky, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Naftidrofuryl in Chronic Arterial Disease. Results of a Controlled Multicenter Study</atitle><jtitle>Angiology</jtitle><addtitle>Angiology</addtitle><date>1984-11</date><risdate>1984</risdate><volume>35</volume><issue>11</issue><spage>701</spage><epage>708</epage><pages>701-708</pages><issn>0003-3197</issn><eissn>1940-1574</eissn><abstract>In a double blind, randomized multicenter study naftidrofuryl, a vasoactive substance, was compared with placebo in the treatment of 104 patients with chronic arterial occlusive disease. After a run-in period of four weeks the pa tients received either naftidrofuryl (600mg daily) or placebo over 12 weeks. The pain-free and the total walking distances improved significantly in both groups. However, the difference in the improvement of the pain-free walking distance was significant (p &lt; 0.02) in favour of naftidrofuryl. There also was a difference in the improvement of the total walking distance in favour of naftidrofuryl which was not significant. The results indicate that naftidrofuryl has a beneficial effect on the symp toms and lengthens the painfree walking distance in patients with arterial occlu sive disease.</abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><pmid>6388425</pmid><doi>10.1177/000331978403501103</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-3197
ispartof Angiology, 1984-11, Vol.35 (11), p.701-708
issn 0003-3197
1940-1574
language eng
recordid cdi_proquest_miscellaneous_81335621
source SAGE Complete Deep Backfile Purchase 2012
subjects Adult
Arterial Occlusive Diseases - drug therapy
Blood Flow Velocity
Blood Pressure
Chronic Disease
Clinical Trials as Topic
Double-Blind Method
Female
Furans - therapeutic use
Humans
Male
Middle Aged
Nafronyl - therapeutic use
Placebos
Statistics as Topic
title Naftidrofuryl in Chronic Arterial Disease. Results of a Controlled Multicenter Study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T20%3A09%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Naftidrofuryl%20in%20Chronic%20Arterial%20Disease.%20Results%20of%20a%20Controlled%20Multicenter%20Study&rft.jtitle=Angiology&rft.au=Tr%C3%BCbestein,%20G.&rft.date=1984-11&rft.volume=35&rft.issue=11&rft.spage=701&rft.epage=708&rft.pages=701-708&rft.issn=0003-3197&rft.eissn=1940-1574&rft_id=info:doi/10.1177/000331978403501103&rft_dat=%3Cproquest_cross%3E20071702%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c369t-f133da0b9e22ee8325765ff57e6ede439f2d0cfa9fd14b5c8e076d32ccb27c4b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20071702&rft_id=info:pmid/6388425&rft_sage_id=10.1177_000331978403501103&rfr_iscdi=true